Aerie Pharmaceuticals - Company & Market Research Reports

Aerie Pharmaceuticals is a company that focuses on the development and commercialization of therapies for the treatment of glaucoma and other eye diseases. The National Eye Institute expects the number of people in the United States suffering from glaucoma to reach 4.3 million by 2030. Aerie was founded in 2005 and went in public in 2013, raising $67 million in its IPO. Its product candidates include Rhopressa and Roclatan. The company is headquartered in Irvine, California.

From
From
From
From
From
From
From
From
From
From
Glaucoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 299 Pages
From
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
From
From
Loading Indicator
adroll